Philippe JEAN-PIERRE

---

• Type de publi. : Article dans une revue
• Date de publi. : 07/09/2021
• Auteurs : Guillaume CoutanceNicolas NesselerErwan FlecherAndré VincentelliCéline GoeminneClément DelmasJean PorterieKarine NubretMathieu PernotMichel KindoTam Hoang MinhPhilippe RouvièrePhilippe GaudardMagali MichelThomas SénageAude BoignardOlivier ChavanonMarylou ParaConstance VerdonkEdeline PelcéVlad GariboldiFrédéric AnselmePierre‐yves LitzlerKatrien BlanchartGerard BabatasiMarie BielefeldOlivier BouchotDavid HamonNicolas LelloucheXavier BailleulThibaud GenetRomain EschalierNicolas D’ostrevyMarie‐cécile BoriesRamzi Abi AkarHugues BlangyFabrice VanhuyseJean François ObadiaVincent GalandMatteo Pozzi
• Organismes : Hospices Civils de Lyon Hôpital Louis Pradel [CHU - HCL] Laboratoire Traitement du Signal et de l'Image Laboratoire Traitement du Signal et de l'Image Institut Coeur Poumon [CHU Lille] Institut Coeur Poumon [CHU Lille] Centre Hospitalier Universitaire de Toulouse Centre Hospitalier Universitaire de Toulouse Hôpital Haut-Lévêque [CHU Bordeaux] Université de Bordeaux Hôpital Haut-Lévêque [CHU Bordeaux] Université de Bordeaux Hôpitaux Universitaires de Strasbourg Hôpitaux Universitaires de Strasbourg Hôpital Arnaud de Villeneuve [CHU Montpellier] Hôpital Arnaud de Villeneuve [CHU Montpellier] Centre Hospitalier Universitaire de Nantes = Nantes University Hospital Centre Hospitalier Universitaire de Nantes = Nantes University Hospital Hôpital Michallon Hôpital Michallon AP-HP - Hôpital Bichat - Claude Bernard [Paris] AP-HP - Hôpital Bichat - Claude Bernard [Paris] Hôpital de la Timone [CHU - APHM] Hôpital de la Timone [CHU - APHM] Hôpital Charles Nicolle [Rouen] Hôpital Charles Nicolle [Rouen] Université de Caen Normandie CHU Caen Normandie – Centre Hospitalier Universitaire de Caen Normandie Université de Caen Normandie CHU Caen Normandie – Centre Hospitalier Universitaire de Caen Normandie CHU Dijon CHU Dijon CHU Henri Mondor [Créteil] CHU Henri Mondor [Créteil] CHU Trousseau [Tours] CHU Trousseau [Tours] CHU Clermont-Ferrand CHU Clermont-Ferrand Hôpital Européen Georges Pompidou [APHP] Hôpital Européen Georges Pompidou [APHP] Centre Hospitalier Universitaire de Nancy Centre Hospitalier Régional Universitaire de Nancy Centre Hospitalier Universitaire de Nancy Centre Hospitalier Régional Universitaire de Nancy Hospices Civils de Lyon Hôpital Louis Pradel [CHU - HCL] Laboratoire Traitement du Signal et de l'Image Hôpital Louis Pradel [CHU - HCL]
• Publié dans ESC Heart Failure le 04/04/2018

---

Résumé : Aims: Despite regularly updated guidelines, there is still a delay in referral of advanced heart failure patients to mechanical circulatory support and transplant centres. We aimed to analyse characteristics and outcome of non-inotrope-dependent patients implanted with a left ventricular assist device (LVAD).Methods and results: The ASSIST-ICD registry collected LVAD data in 19 centres in France between February 2006 and December 2016. We used data of patients in Interagency Registry for Mechanically Assisted Circulatory Support Classes 4-7. The primary endpoint was survival analysis. Predictors of mortality were searched with multivariable analyses. A total of 303 patients (mean age 61.0 ± 9.9 years, male sex 86.8%) were included in the present analysis. Ischaemic cardiomyopathy was the leading heart failure aetiology (64%), and bridge to transplantation was the main implantation strategy (56.1%). The overall likelihood of being alive while on LVAD support or having a transplant at 1, 2, 3, and 5 years was 66%, 61.7%, 58.7%, and 55.1%, respectively. Age [hazard ratio (HR) 1.03, 95% confidence interval (CI) 1.00-1.05; P = 0.02], a concomitant procedure (HR 2.32, 95% CI 1.52-3.53; P < 0.0001), and temporary mechanical right ventricular support during LVAD implantation (HR 2.94, 95% CI 1.49-5.77; P = 0.002) were the only independent variables associated with mortality. Heart failure medications before or after LVAD implantation were not associated with survival.Conclusion: Ambulatory heart failure patients displayed unsatisfactory survival rates after LVAD implantation. A better selection of patients who can benefit from LVAD may help improving outcomes.

---

Fichiers liés : 2021 Baudry et al;, Characteristics and outcome.pdf

---

Source

---

• Type de publi. : Communication dans un congrès
• Date de publi. : 06/09/2021
• Auteurs : Gilles MartelPierre MischlerDaphné DurantJean-Philippe Choisis
• Organismes : Biodiversité agroécologie et aménagement du paysage Institut de l'élevage Domaine expérimental de Saint-Laurent-de-la-Prée Systèmes d'élevage méditerranéens et tropicaux

---

Fichiers liés : OWC2020-SCI-666-preview-2.pdf

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 06/09/2021
• Auteurs : Laurence SalleClaire MillotteMarion VergonjeanneMichel Druet-CabanacMarie PerrierMartine GravelatMonique Dupont-CuisinierCatherine Le FlahecJean- Claude DesportFayemendy PhilippePierre Jésus
• Organismes : Service de Médecine interne B, Endocrinologie, Diabète, Maladies métaboliques [CHU Limoges] Neuroépidémiologie Tropicale Neuroépidémiologie Tropicale Service de Santé au Travail [CHU Limoges] Service d'Hépato-gastro-entérologie et Nutrition [CHU Dupuytren 1, Limoges] Neuroépidémiologie Tropicale Neuroépidémiologie Tropicale Service d'Hépato-gastro-entérologie et Nutrition [CHU Dupuytren 1, Limoges] Neuroépidémiologie Tropicale Service d'Hépato-gastro-entérologie et Nutrition [CHU Dupuytren 1, Limoges]
• Publié dans Eating and Weight Disorders - Studies on Anorexia, Bulimia and Obesity le 31/10/2020

---

Résumé : Purpose: Obesity is a public health problem worldwide. The eating habits of French workers need to be clarified. In particular, tachyphagia (meal lasting < 15 min) promotes weight gain. The present study aimed to investigate the presence of tachyphagia at lunchtime, the factors associated with tachyphagia, and the relationship between tachyphagia and obesity among workers. Methods: This cross-sectional study was conducted between January and May 2016 in five departments of occupational medicine. An anonymous self-administered questionnaire was used to gather general declarative data, such as weight and height (to calculate body mass index [BMI]) and information about lunchtime habits, including the time spent eating. Results: A total of 415 workers with a mean age of 41.1 ± 12.6 years were included. The mean BMI was 23.8 ± 4.6 kg/m2, and the prevalence of obesity was 15.9%. Tachyphagia occurred in 20.3% of the cases and was more frequent in younger workers. Multivariate analysis revealed that skipping meals, eating standing up, and eating fast food were positively associated with tachyphagia (p = 0.015, p = 0.028, and p = 0.027, respectively). Older age and eating with colleagues/friends were negatively associated with tachyphagia (p = 0.003 and p < 0.0001, respectively). No significant association was observed between tachyphagia and obesity. Conclusion: Our study provides important information about the lunchtime habits of workers. Maintaining commensality is crucial, particularly in young workers. Companies should play a role in organising their employees' lunch breaks. Level III Evidence obtained from well-designed cohort or case-control analytic studies.

---

Source

---

• Type de publi. : Rapport
• Date de publi. : 06/09/2021
• Auteurs : . Comité Scientifique Du Haut Conseil Des BiotechnologiesFrédérique AngevinClaude BagnisAvner Bar-HenMarie-Anne BarnyPascal BoireauThierry BrévaultBruno ChauvelCécile CollonnierDenis CouvetElie DassaHubert de VerneuilClaudine FranchePhilippe GuercheJoël GuillemainGuillermina Hernandez-RaquetJamal KhalifeBernard KlonjkowskiMarc LavielleValérie Le CorreFrançois LefèvreOlivier LemaireDidier LereclusRémy MaximilienEliane MeursNadia NaffakhDidier NégreSergio OchattJean-Christophe PagesXavier RaynaudCatherine Regnault-RogerMichel M. RenardTristan RenaultPatrick SaindrenanPascal SimonetMarie-Bérengère TroadecBernard E. VaissièreJean-Luc Vilotte
• Organismes : Haut Conseil des Biotechnologies Unité Impacts Ecologiques des Innovations en Production Végétale Haut Conseil des Biotechnologies Etablissement Français du Sang Haut Conseil des Biotechnologies Université Paris-Sud - Paris 11 Université Paris Descartes - Paris 5 Haut Conseil des Biotechnologies Haut Conseil des Biotechnologies Institut d'écologie et des sciences de l'environnement de Paris Direction des Ressources Humaines et du Développement Durable Haut Conseil des Biotechnologies Haut Conseil des Biotechnologies Agroécologie et intensification durables des cultures annuelles Département Performances des systèmes de production et de transformation tropicaux Haut Conseil des Biotechnologies Agroécologie [Dijon] Haut Conseil des Biotechnologies Institut Jean-Pierre Bourgin - Sciences du végétal Muséum national d'Histoire naturelle Haut Conseil des Biotechnologies Institut National de la Santé et de la Recherche Médicale Haut Conseil des Biotechnologies Institut National de la Santé et de la Recherche Médicale Haut Conseil des Biotechnologies Institut de Recherche pour le Développement Haut Conseil des Biotechnologies Haut Conseil des Biotechnologies Institut Jean-Pierre Bourgin - Sciences du végétal Agence nationale de sécurité du médicament et des produits de santé [Saint-Denis] Université de Tours Haut Conseil des Biotechnologies Laboratoire d'Ingénierie des Systèmes Biologiques et des Procédés Haut Conseil des Biotechnologies Centre National de la Recherche Scientifique Institut Pasteur de Lille Virologie UMR1161 Haut Conseil des Biotechnologies Haut Conseil des Biotechnologies Modélisation en pharmacologie de population Haut Conseil des Biotechnologies Agroécologie [Dijon] Haut Conseil des Biotechnologies Virologie et Immunologie Moléculaires Santé de la vigne et qualité du vin Haut Conseil des Biotechnologies MICrobiologie de l'ALImentation au Service de la Santé Haut Conseil des Biotechnologies Commissariat à l'énergie atomique et aux énergies alternatives Haut Conseil des Biotechnologies Institut Pasteur [Paris] Centre National de la Recherche Scientifique Haut Conseil des Biotechnologies Centre National de la Recherche Scientifique Haut Conseil des Biotechnologies Haut Conseil des Biotechnologies Agroécologie [Dijon] Université de Tours Etablissement Français du Sang Haut Conseil des Biotechnologies Haut Conseil des Biotechnologies Institut d'écologie et des sciences de l'environnement de Paris Haut Conseil des Biotechnologies Institut de Génétique, Environnement et Protection des Plantes Haut Conseil des Biotechnologies Agence nationale de sécurité sanitaire de l'alimentation, de l'environnement et du travail Institut Français de Recherche pour l'Exploitation de la Mer Haut Conseil des Biotechnologies Haut Conseil des Biotechnologies Institut des Sciences des Plantes de Paris-Saclay Centre National de la Recherche Scientifique Haut Conseil des Biotechnologies Centre National de la Recherche Scientifique Haut Conseil des Biotechnologies Abeilles et Environnement Haut Conseil des Biotechnologies Génétique Animale et Biologie Intégrative Haut Conseil des Biotechnologies

---

Résumé : Le Haut Conseil des biotechnologies (HCB) a été saisi le 22 juin 2021 par les autorités compétentes françaises (Ministère de l'Agriculture et de l'Alimentation) d'une demande d'avis relative au dossier EFSA-GMO-NL-2020-172 de demande d'autorisation de mise sur le marché du maïs génétiquement modifié DP915635 à des fins d'importation, transformation et alimentation humaine et animale. Ce dossier a été déposé par la société Pioneer Hi-Bred International, Inc. auprès des autorités compétentes néerlandaises sur le fondement du règlement (CE) n° 1829/2003. Dans le cadre de ce règlement, l'évaluation des dossiers de demande de mise sur le marché est confiée à l'Autorité européenne de sécurité des aliments (EFSA). Les Etats membres disposent de trois mois pour envoyer leurs commentaires à l'EFSA en contribution à l'évaluation du dossier. Dans ce contexte, le HCB est invité à proposer des commentaires à destination de l'EFSA au plus tard le 07 septembre 2021.

---

Fichiers liés : 20210906avismaisdp915635cs210826.pdf

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 04/09/2021
• Auteurs : Fabien MalbetCéline BoehmAlberto Krone-MartinsAntonio AmorimGuillem Anglada-EscudéAlexis BrandekerFrédéric CourbinTorsten EnsslinAntonio FalcãoKatherine FreeseBerry HollLucas LabadieAlain LégerGary A MamonBarbara McarthurAlcione MoraMike ShaoAlessandro SozzettiDouglas SpolyarEva VillaverUmmi AbbasConrado AlbertusJoão AlvesRory BarnesAldo Stefano BonomoHervé BouyWarren R BrownVitor CardosoMarco CastellaniL. CheminHamish ClarkAlexandre C M CorreiaMariateresa CrostaAntoine CrouzierMario DamassoJeremy DarlingMelvyn B DaviesAntonaldo DiaferioMorgane FortinMalcolm FridlundMario GaiPaulo GarciaOleg GnedinAriel GoobarPaulo GordoRenaud GoullioudFabrizia GuglielmettiNigel HamblyDiana HarrisonDavid HobbsRodrigo A IbataErik HøgCarme JordiSergei KlionerA. LanconJacques LaskarMario LattanziChristophe Le Poncin-LafitteXavier LuriDaniel MichalikAndré Moitinho de AlmeidaAna MourãoLeonidas MoustakasNeil J MurrayMatthew MuterspaughMicaela OertelLuisa OstoreroJordi PortellJean-Pierre ProstAndreas QuirrenbachJean SchneiderPat ScottArnaud SiebertAntonio Da SilvaManuel SilvaPhilippe ThébaultJohn TomsickWesley TraubMiguel de Val-BorroMonica ValluriNicholas A WaltonLaura L WatkinsGlenn WhiteLukasz WyrzykowskiRosemary WyseYoshiyuki Yamada
• Organismes : Institut de Planétologie et d'Astrophysique de Grenoble School of Physics [Sydney] Centro de Astrofísica e Gravitação [Instituto Superior Técnico, Lisboa] = Center for Astrophysics and Gravitation [Lisbon] Centro de Astrofísica e Gravitação [Instituto Superior Técnico, Lisboa] = Center for Astrophysics and Gravitation [Lisbon] Queen Mary University of London Stockholm University Ecole Polytechnique Fédérale de Lausanne Max Planck Institute for Astrophysics UNINOVA / CTS, Campus FCT/UNL Stockholm University University of Texas at Austin [Austin] Observatoire Astronomique de l'Université de Genève Universität zu Köln = University of Cologne Institut d'astrophysique spatiale Institut d'Astrophysique de Paris University of Texas at Austin [Austin] Aurora Technology BV Jet Propulsion Laboratory INAF - Osservatorio Astrofisico di Torino Stockholm University Centro de Astrobiologia [Madrid] INAF - Osservatorio Astrofisico di Torino Universidad de Granada = University of Granada Universität Wien = University of Vienna Department of Astronomy [Seattle] INAF - Osservatorio Astrofisico di Torino Laboratoire d'Astrophysique de Bordeaux [Pessac] Harvard-Smithsonian Center for Astrophysics Centro de Astrofísica e Gravitação [Instituto Superior Técnico, Lisboa] = Center for Astrophysics and Gravitation [Lisbon] INAF - Osservatorio Astronomico di Roma University of Antofogasta The University of Sydney Universidade de Coimbra = University of Coimbra [Portugal] INAF - Osservatorio Astrofisico di Torino Laboratoire d'études spatiales et d'instrumentation en astrophysique = Laboratory of Space Studies and Instrumentation in Astrophysics INAF - Osservatorio Astrofisico di Torino University of Colorado [Boulder] Skane University Hospital [Lund] Dipartimento di Fisica [Torino] Istituto Nazionale di Fisica Nucleare, Sezione di Torino Copernicus Astronomical Center of the Polish Academy of Sciences Leiden Observatory [Leiden] Chalmers University of Technology [Gothenburg, Sweden] INAF - Osservatorio Astrofisico di Torino Faculdade de Engenharia da Universidade do Porto Université du Michigan = University of Michigan [Ann Arbor] Stockholm University Centro de Astrofísica e Gravitação [Instituto Superior Técnico, Lisboa] = Center for Astrophysics and Gravitation [Lisbon] Jet Propulsion Laboratory The Open University [Milton Keynes, UK] The University of Edinburgh Institute of Astronomy [Cambridge] Lund Observatory The Open University [Milton Keynes, UK] Niels Bohr Institute [Copenhagen] Institut de Ciencies del Cosmos Lohrmann Observatory Observatoire astronomique de Strasbourg Institut de Mécanique Céleste et de Calcul des Ephémérides INAF - Osservatorio Astrofisico di Torino Systèmes de Référence Temps Espace Institut de Ciencies del Cosmos ESA - ESTEC (Netherlands) Centro de Astrofísica e Gravitação [Instituto Superior Técnico, Lisboa] = Center for Astrophysics and Gravitation [Lisbon] Centro de Astrofísica e Gravitação [Instituto Superior Técnico, Lisboa] = Center for Astrophysics and Gravitation [Lisbon] Jet Propulsion Laboratory The Open University [Milton Keynes, UK] Columbia State Community College Laboratoire Univers et Théories Dipartimento di Fisica [Torino] Istituto Nazionale di Fisica Nucleare, Sezione di Torino Institut de Ciencies del Cosmos Thales Alenia Space [Toulouse] Universität Heidelberg [Heidelberg] = Heidelberg University Laboratoire Univers et Théories The University of Queensland Imperial College London Observatoire astronomique de Strasbourg Instituto de Astrofísica e Ciências do Espaço Faculdade de Engenharia da Universidade do Porto Laboratoire d'études spatiales et d'instrumentation en astrophysique = Laboratory of Space Studies and Instrumentation in Astrophysics Space Sciences Laboratory [Berkeley] Jet Propulsion Laboratory Planetary Science Institute [Tucson] Université du Michigan = University of Michigan [Ann Arbor] Institute of Astronomy [Cambridge] Space Telescope Science Institute Space Science and Technology Department [Didcot] The Open University [Milton Keynes, UK] Astronomical Observatory [Warsaw] Johns Hopkins University [Baltimore] Department of Physics [Kyoto]
• Publié dans Experimental Astronomy le 29/10/2020

---

Résumé : Sky survey telescopes and powerful targeted telescopes play complementary roles in astronomy. In order to investigate the nature and characteristics of the motions of very faint objects, a flexibly-pointed instrument capable of high astrometric accuracy is an ideal complement to current astrometric surveys and a unique tool for precision astrophysics. Such a space-based mission will push the frontier of precision astrometry from evidence of Earth-mass habitable worlds around the nearest stars, to distant Milky Way objects, and out to the Local Group of galaxies. As we enter the era of the James Webb Space Telescope and the new ground-based, adaptive-optics-enabled giant telescopes, by obtaining these high precision measurements on key objects that Gaia could not reach, a mission that focuses on high precision astrometry science can consolidate our theoretical understanding of the local Universe, enable extrapolation of physical processes to remote redshifts, and derive a much more consistent picture of cosmological evolution and the likely fate of our cosmos. Already several missions have been proposed to address the science case of faint objects in motion using high precision astrometry missions: NEAT proposed for the ESA M3 opportunity, micro-NEAT for the S1 opportunity, and Theia for the M4 and M5 opportunities. Additional new mission configurations adapted with technological innovations could be envisioned to pursue accurate measurements of these extremely small motions. The goal of this White Paper is to address the fundamental science questions that are at stake when we focus on the motions of faint sky objects and to briefly review instrumentation and mission profiles.

---

Fichiers liés : EXPA_malbet_SI_Voyage2050.pdf

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 03/09/2021
• Auteurs : Yassir BenhimaPhilippe SénacJean-Pierre van Staëvel
• Organismes : Histoire, Archéologie et Littératures des mondes chrétiens et musulmans médiévaux Université Sorbonne Nouvelle - Paris 3 Centre de Recherche Roland Mousnier Histoire et Civilisation Université Sorbonne Nouvelle - Paris 3 ORIENT ET MÉDITERRANÉE : Textes, Archéologie, Histoire Université Paris 1 Panthéon-Sorbonne
• Publié dans Revue des Mondes Musulmans et de la Méditerranée le 28/10/2020

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 03/09/2021
• Auteurs : Boun Kim TanMathieu ChalouniDominique Salmon CeronAlexandre CinaudLaure EsterleMarc Arthur LokoChristine KatlamaIsabelle Poizot-MartinDidier NeauJulie ChasPhilippe MorlatEric RosenthalKarine LacombeAlissa NaqviKarl BarangeOlivier BouchaudAnne GervaisCaroline Lascoux-CombeDaniel GaripuyLaurent AlricCécile GoujardPatrick MiailhesHugues AumaitreClaudine DuvivierAnne SimonJose-Luis Lopez-ZaragozaDavid ZucmanFrançois RaffiEstibaliz LazaroDavid ReyLionel PirothFrançois BouéCamille GilbertFirouzé Bani-SadrFrançois DabisPhilippe SogniLinda WittkopFranck Boccara
• Organismes : Hôpital Cochin [AP-HP] Hôpitaux Universitaires Paris Centre Université Paris Descartes - Paris 5 Team MORPH3EUS Université de Bordeaux Hôpitaux Universitaires Paris Centre Université Paris Descartes - Paris 5 Université Paris Descartes - Paris 5 Hôtel-Dieu Team MORPH3EUS Université de Bordeaux Team MORPH3EUS Université de Bordeaux CHU Pitié-Salpêtrière [AP-HP] Institut Pierre Louis d'Epidémiologie et de Santé Publique Hôpital Sainte-Marguerite [CHU - APHM] Sciences Economiques et Sociales de la Santé & Traitement de l'Information Médicale Hôpital Pellegrin Université de Bordeaux CHU Tenon [AP-HP] Team MORPH3EUS Université de Bordeaux Hôpital Saint-André [Bordeaux] Hôpital l'Archet Université de Nice Sophia-Antipolis Institut Pierre Louis d'Epidémiologie et de Santé Publique CHU Saint-Antoine [AP-HP] Hôpital l'Archet Centre Hospitalier Universitaire de Toulouse Hôpital Avicenne [AP-HP] Université Sorbonne Paris Nord AP-HP - Hôpital Bichat - Claude Bernard [Paris] Hopital Saint-Louis [AP-HP] Centre Hospitalier Universitaire de Toulouse Centre Hospitalier Universitaire de Toulouse Pharmacochimie et Biologie pour le Développement Hôpital Bicêtre [AP-HP, Le Kremlin-Bicêtre] Université Paris-Saclay Hôpital de la Croix-Rousse [CHU - HCL] Centre Hospitalier Saint Jean de Perpignan Imagine - Institut des maladies génétiques (IHU) CHU Pitié-Salpêtrière [AP-HP] Hôpital Henri Mondor Hôpital Foch [Suresnes] Centre d’Investigation Clinique de Nantes Hôpital Pellegrin Hôpital Haut-Lévêque [CHU Bordeaux] Le Trait d'Union, centre de soins de l'infection par le VIH [CHU Strasbourg] CHU Dijon Université de Bourgogne Université Paris-Saclay AP-HP - Hôpital Antoine Béclère [Clamart] Team MORPH3EUS Hôpital universitaire Robert Debré [Reims] Infections Cardiovasculaires Virales et inflammation en pathologie humaine (CardioVir) UMR-S 1320 Team MORPH3EUS Université Paris Descartes - Paris 5 Hôpital Cochin [AP-HP] Immunité Innée - Innate Immunity Team MORPH3EUS Centre Hospitalier Universitaire de Bordeaux CHU Saint-Antoine [AP-HP] Université Sorbonne Paris Cité Pathologies biliaires, fibrose et cancer du foie [CRSA]
• Publié dans Clinical Infectious Diseases le 30/10/2020

---

Résumé : Background: An increased risk of cardiovascular disease (CVD) was reported in patients coinfected with human immunodeficiency virus (HIV) and hepatitis C virus (HCV), without identifying factors associated with atherosclerotic CVD (ASCVD) events. Methods: HIV-HCV coinfected patients were enrolled in the Agence Nationale de Recherches sur le Sida et les hépatites virales (ANRS) CO13 HEPAVIH nationwide cohort. Primary outcome was total ASCVD events. Secondary outcomes were coronary and/or cerebral ASCVD events, and peripheral artery disease (PAD) ASCVD events. Incidences were estimated using the Aalen-Johansen method. Factors associated with ASCVD were identified using cause-specific Cox proportional hazards models. Results: At baseline, median age of the study population (N = 1213) was 45.4 (interquartile range [IQR] 42.1-49.0) years and 70.3% were men. After a median follow-up of 5.1 (IQR 3.9-7.0) years, the incidence was 6.98 (95% confidence interval [CI], 5.19-9.38) per 1000 person-years for total ASCVD events, 4.01 (2.78-6.00) for coronary and/or cerebral events, and 3.17 (2.05-4.92) for PAD ASCVD events. Aging (hazard ratio [HR] 1.06; 95% CI, 1.01-1.12), prior CVD (HR 8.48; 95% CI, 3.14-22.91), high total cholesterol (HR 1.43; 95% CI, 1.11-1.83), high-density lipoprotein cholesterol (HR 0.22; 95% CI, 0.08-0.63), statin use (HR 3.31; 95% CI, 1.31-8.38), and high alcohol intake (HR 3.18; 95% CI, 1.35-7.52) were independently associated with total ASCVD events, whereas undetectable baseline viral load (HR 0.41, 95% CI, 0.18-0.96) was associated with coronary and/or cerebral events. Conclusions: HIV-HCV coinfected patients experienced a high incidence of ASCVD events. Some traditional cardiovascular risk factors were the main determinants of ASCVD. Controlling cholesterol abnormalities and maintaining undetectable HIV RNA are essential to control cardiovascular risk.

---

Fichiers liés : ciaa1014.pdf

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 03/09/2021
• Auteurs : R Thomas LumbersSonia ShahHonghuang LinTomasz CzubaAlbert HenryDaniel I SwerdlowAnders MälarstigCharlotte AnderssonNiek VerweijMichael V HolmesJohan ÄrnlövHarry HemingwayNeneh SallahPeter AlmgrenKrishna G AragamGeraldine AsselinJoshua D BackmanMary L BiggsHeather L BloomEric BoersmaJeffrey BrandimartoMichael R BrownHans-Peter Brunner-La RoccaDavid J CareyMark D ChaffinDaniel I ChasmanOlympe ChazaraXing ChenXu ChenJonathan H ChungWilliam ChutkowJohn G F ClelandJames P CookSimon de DenusAbbas DehghanGraciela E DelgadoSpiros DenaxasAlexander S DoneyMarcus DörrSamuel C DudleyGunnar EngströmTõnu EskoGhazaleh FatemifarStephan B FelixChris FinanIan FordFrançoise FougerousseRené FouodjioMohsen GhanbariSahar GhasemiVilmantas GiedraitisFranco GiulianiniJohn S GottdienerStefan GrossDaníel F GuðbjartssonHongsheng GuiRebecca GutmannChristopher M HaggertyPim van Der HarstÅsa K HedmanAnna HelgadottirHans HillegeCraig L HydeJaison JacobJ Wouter JukemaFrederick KamanuIsabella KardysMaryam KavousiKay-Tee KhawMarcus E KleberLars KøberAndrea KoekemoerBill KrausKaroline KuchenbaeckerClaudia LangenbergLars LindCecilia M LindgrenBarry LondonLuca A LottaRuth C LoveringJian'An LuanPatrik MagnussonAnubha MahajanDouglas MannKenneth B MarguliesNicholas A MarstonWinfried MärzJohn J V McmurrayOlle MelanderGiorgio MelloniIfy R MordiMichael P MorleyAndrew D MorrisAlanna C MorrisonMichael W NagleChristopher P NelsonChristopher Newton-ChehAlexander NiessnerTeemu NiiranenChristoph NowakMichelle L O'DonoghueAnjali T OwensColin N A PalmerGuillaume ParéMarkus PerolaLouis-Philippe Lemieux PerreaultEliana Portilla-FernandezBruce M PsatyKenneth M RicePaul M RidkerSimon P R RomaineCarolina RoselliJerome I RotterChristian T RuffMarc S SabatinePerttu SaloVeikko SalomaaJessica van SettenAlaa A ShalabyDiane T SmelserNicholas L SmithKari StefanssonSteen StenderDavid J StottGarðar SveinbjörnssonMari-Liis TammesooJean-Claude TardifKent D TaylorMaris Teder-LavingAlexander TeumerGuðmundur ThorgeirssonUnnur ThorsteinsdottirChristian Torp-PedersenStella TrompetDanny TuckwellBenoit TylAndre G UitterlindenFelix VauraAbirami VeluchamyPeter M VisscherUwe VölkerAdriaan A VoorsXiaosong WangNicholas J WarehamPeter E WeekeRaul WeissHarvey D WhiteKerri L WigginsHeming XingJian YangYifan YangLaura M Yerges-ArmstrongBing YuFaiez ZannadFaye ZhaoRegeneron Genetics CenterJemma B WilkHilma HolmNaveed SattarSteven A LubitzDavid E LanfearSvati ShahMichael E DunnQuinn S WellsFolkert W AsselbergsAroon D HingoraniMarie-Pierre DubéNilesh SamaniChim C LangThomas P CappolaPatrick T EllinorRamachandran S VasanJ Gustav Smith
• Organismes : University College London [UCL] University College London Hospitals Boston University School of Medicine Skane University Hospital [Lund] University College London [UCL] University College London [UCL] Pfizer Karolinska Institutet [Stockholm] Broad Institute of MIT and Harvard University of Groningen [Groningen] University of Oxford Dalarna University Karolinska Institutet [Stockholm] University College London [UCL] University College London [UCL] Skane University Hospital [Lund] Massachusetts General Hospital [Boston] Broad Institute of MIT and Harvard Montreal Heart Institute - Institut de Cardiologie de Montréal Regeneron Genetics Center, 777 Old Saw Mill River Road, Tarrytown University of Washington [Seattle] Emory University [Atlanta, GA] Erasmus University Medical Center [Rotterdam] University of Pennsylvania [Philadelphia] The University of Texas Health Science Center at Houston Maastricht University Medical Centre Department of Molecular and Functional Genomics, Geisinger, Danville, PA Broad Institute of MIT and Harvard Brigham & Women’s Hospital [Boston] AstraZeneca Pfizer Karolinska Institutet [Stockholm] Regeneron Genetics Center, 777 Old Saw Mill River Road, Tarrytown Novartis Institutes for BioMedical Research University of Glasgow University of Liverpool Montreal Heart Institute - Institut de Cardiologie de Montréal Université de Montréal Imperial College London University of Heidelberg, Medical Faculty University College London [UCL] University of Dundee Universität Greifswald = University of Greifswald University of Minnesota Medical School Skane University Hospital [Lund] Broad Institute of MIT and Harvard Massachusetts General Hospital [Boston] University College London [UCL] Universität Greifswald = University of Greifswald German Center for Cardiovascular Research University College London [UCL] University of Glasgow Institut de Recherches Internationales Servier [Suresnes] Montreal Heart Institute - Institut de Cardiologie de Montréal Erasmus University Medical Center [Rotterdam] German Center for Cardiovascular Research Universität Greifswald = University of Greifswald Uppsala University Brigham & Women’s Hospital [Boston] University of Maryland School of Medicine Universität Greifswald = University of Greifswald University of Iceland [Reykjavik] deCODE genetics [Reykjavik] Henry Ford Hospital Carver College of Medicine, University of Iowa Geisinger Autism & Developmental Medicine Institute [Danville, PA, USA] University of Groningen [Groningen] ICIN - Netherlands Heart Institute Karolinska Institutet [Stockholm] deCODE genetics [Reykjavik] University of Groningen [Groningen] Pfizer Novartis Institutes for BioMedical Research Leiden University Medical Center [Leiden] Netherlands Heart Institute Broad Institute of MIT and Harvard Brigham & Women’s Hospital [Boston] Erasmus University Medical Center [Rotterdam] Erasmus University Medical Center [Rotterdam] University of Cambridge [Cambridge, UK] University of Heidelberg, Medical Faculty Rigshospitalet [Copenhagen, Denmark] University of Leicester Duke University [Durham] University College London [UCL] University of Cambridge [Cambridge, UK] Uppsala University Broad Institute of MIT and Harvard University of Oxford University of Iowa [Iowa City] University of Cambridge [Cambridge, UK] University College London [UCL] University of Cambridge [Cambridge, UK] Karolinska Institutet [Stockholm] Genentech, Inc. Washington University School of Medicine in St. Louis University of Pennsylvania [Philadelphia] Brigham & Women’s Hospital [Boston] University of Heidelberg, Medical Faculty University of Glasgow Skane University Hospital [Lund] Skane University Hospital [Malmo] Broad Institute of MIT and Harvard Brigham & Women’s Hospital [Boston] University of Dundee University of Pennsylvania [Philadelphia] The University of Edinburgh The University of Texas Health Science Center at Houston Pfizer University of Leicester Massachusetts General Hospital [Boston] Medical University of Vienna = Medizinische Universität Wien University of Turku National Institute for Health and Welfare [Helsinki] Karolinska Institutet [Stockholm] Brigham & Women’s Hospital [Boston] University of Pennsylvania [Philadelphia] University of Dundee McMaster University [Hamilton, Ontario] National Institute for Health and Welfare [Helsinki] Montreal Heart Institute - Institut de Cardiologie de Montréal Erasmus University Medical Center [Rotterdam] University of Washington [Seattle] Kaiser Permanente Washington Health Research Institute [Seattle] University of Washington [Seattle] Brigham & Women’s Hospital [Boston] Harvard Medical School [Boston] University of Leicester University of Groningen [Groningen] Broad Institute of MIT and Harvard Harbor UCLA Medical Center [Torrance, Ca.] Brigham & Women’s Hospital [Boston] Brigham & Women’s Hospital [Boston] National Institute for Health and Welfare [Helsinki] National Institute for Health and Welfare [Helsinki] University Medical Center [Utrecht] University of Pittsburgh Medical Center [Pittsburgh, PA, États-Unis] Geisinger Autism & Developmental Medicine Institute [Danville, PA, USA] Kaiser Permanente Washington Health Research Institute [Seattle] University of Washington [Seattle] deCODE genetics [Reykjavik] University of Iceland [Reykjavik] Copenhagen University Hospital [Denmark] = Københavns Universitetshospital [Danmark] University of Glasgow deCODE genetics [Reykjavik] Tartu University Hospital Montreal Heart Institute - Institut de Cardiologie de Montréal Université de Montréal Harbor UCLA Medical Center [Torrance, Ca.] Tartu University Hospital German Center for Cardiovascular Research Universität Greifswald = University of Greifswald deCODE genetics [Reykjavik] University of Iceland [Reykjavik] deCODE genetics [Reykjavik] University of Iceland [Reykjavik] Aalborg University Universiteit Leiden = Leiden University Novartis Institutes for BioMedical Research Institut de Recherches Internationales Servier [Suresnes] Erasmus University Medical Center [Rotterdam] National Institute for Health and Welfare [Helsinki] University of Turku University of Dundee The University of Queensland German Center for Cardiovascular Research Universität Greifswald = University of Greifswald University of Groningen [Groningen] Novartis Institutes for BioMedical Research University of Cambridge [Cambridge, UK] Rigshospitalet [Copenhagen, Denmark] The Ohio State University [Columbus] Auckland City Hospital University of Washington [Seattle] Novartis Institutes for BioMedical Research The University of Queensland University of Pennsylvania [Philadelphia] GlaxoSmithKline University of Texas Health Science Center Cardiovascular and Renal Clinical Trialists [Vandoeuvre-les-Nancy] French-Clinical Research Infrastructure Network - F-CRIN [Paris] Institut Lorrain du Coeur et des Vaisseaux Louis Mathieu [Nancy] Défaillance Cardiovasculaire Aiguë et Chronique Novartis Institutes for BioMedical Research Regeneron Genetics Center, 777 Old Saw Mill River Road, Tarrytown Pfizer deCODE genetics [Reykjavik] University of Glasgow Broad Institute of MIT and Harvard Massachusetts General Hospital [Boston] Henry Ford Hospital Duke University [Durham] Duke University Medical Center Regeneron Pharmaceuticals [Tarrytown, NY] Vanderbilt University [Nashville] University College London [UCL] University College London [UCL] Montreal Heart Institute - Institut de Cardiologie de Montréal University of Leicester University of Dundee University of Pennsylvania [Philadelphia] Broad Institute of MIT and Harvard Skane University Hospital [Lund] Skane University Hospital [Lund]
• Publié dans ESC Heart Failure le 04/04/2018

---

Résumé : Aims: The HERMES (HEart failure Molecular Epidemiology for Therapeutic targetS) consortium aims to identify the genomic and molecular basis of heart failure. Methods and results: The consortium currently includes 51 studies from 11 countries, including 68 157 heart failure cases and 949 888 controls, with data on heart failure events and prognosis. All studies collected biological samples and performed genome-wide genotyping of common genetic variants. The enrolment of subjects into participating studies ranged from 1948 to the present day, and the median follow-up following heart failure diagnosis ranged from 2 to 116 months. Forty-nine of 51 individual studies enrolled participants of both sexes; in these studies, participants with heart failure were predominantly male (34-90%). The mean age at diagnosis or ascertainment across all studies ranged from 54 to 84 years. Based on the aggregate sample, we estimated 80% power to genetic variant associations with risk of heart failure with an odds ratio of ≥1.10 for common variants (allele frequency ≥ 0.05) and ≥1.20 for low-frequency variants (allele frequency 0.01-0.05) at P < 5 × 10-8 under an additive genetic model. Conclusions: HERMES is a global collaboration aiming to (i) identify the genetic determinants of heart failure; (ii) generate insights into the causal pathways leading to heart failure and enable genetic approaches to target prioritization; and (iii) develop genomic tools for disease stratification and risk prediction.

---

Fichiers liés : ehf2.13517.pdf

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 02/09/2021
• Auteurs : Hervé JavelotCéline StraczekGuillaume MeyerClara Gitahy Falcao FariaLuisa WeinerDominique DrapierEric FakraPhilippe FossatiSébastien WeibelSophie DizetBastien LangréeM MassonR GaillardMarion LeboyerPierre-Michel LlorcaCoraline HingrayEmmanuel HaffenAntoine Yrondi
• Organismes : Laboratoire de pharmacologie et toxicologie neurocardiovasculaire Institut Mondor de Recherche Biomédicale Centre Hospitalier Universitaire [Strasbourg] Universidade Federal do Rio de Janeiro [Brasil] = Federal University of Rio de Janeiro [Brazil] = Université fédérale de Rio de Janeiro [Brésil] Centre Hospitalier Universitaire [Strasbourg] Laboratoire de Psychologie des Cognitions Comportement et noyaux gris centraux = Behavior and Basal Ganglia [Rennes] Centre Hospitalier Guillaume Régnier [Rennes] Centre Hospitalier Universitaire de Saint-Etienne [CHU Saint-Etienne] Institut du Cerveau = Paris Brain Institute Hôpitaux Universitaires de Strasbourg Centre Hospitalier Chalon-sur-Saône William Morey Centre Hospitalier Guillaume Régnier [Rennes] Groupe hospitalier universitaire Paris psychiatrie & neurosciences [Paris] Conseil national des universités CHU Clermont-Ferrand Université Clermont Auvergne Centre d'Investigation Clinique de Besançon Université de Franche-Comté Toulouse NeuroImaging Center
• Publié dans L'Encéphale le 30/10/2020

---

Résumé : The use of psychotropics during the COVID-19 pandemic has raised two questions, in order of importance: first, what changes should be made to pharmacological treatments prescribed to mental health patients? Secondly, are there any positive side effects of these substances against SARS-CoV-2? Our aim was to analyze usage safety of psychotropics during COVID-19; therefore, herein, we have studied: (i) the risk of symptomatic complications of COVID-19 associated with the use of these drugs, notably central nervous system activity depression, QTc interval enlargement and infectious and thromboembolic complications; (ii) the risk of mistaking the iatrogenic impact of psychotropics with COVID-19 symptoms, causing diagnostic error. Moreover, we provided a summary of the different information available today for these risks, categorized by mental health disorder, for the following: schizophrenia, bipolar disorder, anxiety disorder, ADHD, sleep disorders and suicidal risk. The matter of psychoactive substance use during the pandemic is also analyzed in this paper, and guideline websites and publications for psychotropic treatments in the context of COVID-19 are referenced during the text, so that changes on those guidelines and eventual interaction between psychotropics and COVID-19 treatment medication can be reported and studied. Finally, we also provide a literature review of the latest known antiviral properties of psychotropics against SARS-CoV-2 as complementary information.

---

Fichiers liés : Javelot et al-2021-Psychotropics and COVID-19.pdf

---

Source

---

• Type de publi. : Communication dans un congrès
• Date de publi. : 01/09/2021
• Auteurs : Dérioz PierreLaurent ArcusetPhilippe BachimonYves HascoëtMaud LoireauPhilippe Béringuier
• Organismes : UMR 228 Espace-Dev, Espace pour le développement Université d'Avignon Université d'Avignon UMR 228 Espace-Dev, Espace pour le développement Institut de Recherche pour le Développement (IRD en Occitanie) Université de Perpignan Via Domitia Géographie de l'environnement

---

Source